Challenge of multiple co-primary endpoints: A new approach

Statistics in Medicine

Volumn 26, Issue 6, 2007, Pages 1181-1192

  Chuang Stein, Christy ^a   Stryszak, Paul ^b   Dmitrienko, Alex ^c   Offen, Walter ^c  

^a PFIZER INC   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Average type I error rate; Intersection union test; Prior distribution; Restricted null space; Reverse multiplicity

Indexed keywords

ANALYTICAL ERROR; ARTICLE; CALCULATION; CORRELATION COEFFICIENT; FALSE POSITIVE RESULT; INTERMETHOD COMPARISON; MATHEMATICAL COMPUTING; SAMPLE SIZE; STATISTICAL MODEL;

ALGORITHMS; BIAS (EPIDEMIOLOGY); CLINICAL TRIALS; ENDPOINT DETERMINATION; RESEARCH DESIGN; UNITED STATES;

EID: 33847698947     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.2604     Document Type: Article

References (13)

1. Reitmeir P, Wassmer G. Resampling-based methods for the analysis of multiple endpoints in clinical trials. Statistics in Medicine 1999; 18:3453-3462.
2. Dmitrienko A, Often W, Westfall PH. Gatekeeping strategies for clinical trials that do not require all primary effects to be significant. Statistics in Medicine 2003; 22:2387-2400.
3. Sankoh AJ, D'Agostino RB, Huque MF. Efficacy endpoint selection and multiplicity adjustment methods in clinical trials with inherent multiple endpoints issues. Statistics in Medicine 2003; 22:3133-3150.
4. Often WW, Chuang-Stein C, Dmitrienko A, Littman G, Maca J, Meyerson L, Muirhead R, Stryszak P, Boddy A, Chen K, Copley-Merriman K, Dere W, Givens S, Hall D, Henry D, Jackson J, Krishen A, Liu T, Ryder SW, Sankoh AJ, Wang J, Yeh CH. Multiple co-primary endpoints: medical and statistical solutions. A report from the multiple endpoints expert team of the Pharmaceutical Research and Manufacturers of America. Drug Information Journal 2006, accepted.
5. ICH E9. Statistical principles for clinical trials. Step 5 guidance document available at http://www.ich.org, 2000.
6. CPMP/EWP/908/99. Points to consider on multiplicity issues in clinical trials (adopted September 2002). Available at http://www.emea.eu.int/ pdfs/human/ewp/090899en.pdf, 2002.
7. Berger RL. Multiparameter hypothesis testing and acceptance sampling. Technometrics 1982; 24:295-300.
8. Laska EM, Meisner MJ. Testing whether the identified treatment is best. Biometrics 1989; 45:1139-1151.
9. Leung HM, O'Neill RT. Statistical assessment of combination drugs - a regulatory view. Proceedings of the Annual Meeting of the American Statistical Association, Biopharmaceutical Subsection, 1986; 33-36.
10. Offen WW, Helterbrand JD. Multiple comparison adjustments when two or more co-primary endpoints must all be statistically significant. Proceedings of the Annual Meeting of the American Statistical Association, Biopharmaceutical Subsection, 2003.
11. Pate HI. Comparison of treatments in a combination therapy trial. Journal of Biopharmaceutical Statistics 1991; 1(2):171-183.
12. Snapinn SM, Sarkar SK. Assessing the superiority of a combination drug with a specific alternative. Journal of Biopharmaceutical Statistics 1996; 6:241-251.
13. Genz A, Bretz F. Methods for the computation of multivariate t-probabilities. Journal of Computational and Graphical Statistics 2002; 11:950-971.